Screener
Corcept Therapeutics CORT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Preferred stock | — | — |
| Common stock | 142 | 140 |
| Treasury stock | (998,013) | (966,586) |
| Additional paid-in capital | 1,048,598 | 968,600 |
| Accumulated other comprehensive income | 436 | 2,264 |
| Retained earnings | 654,613 | 643,387 |
| Total stockholders’ equity | 705,776 | 647,805 |
| Total liabilities and stockholders’ equity | $888,702 | $836,651 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's total liabilities & equity?
- Corcept Therapeutics (CORT) reported total liabilities & equity of $888.7M in Q2 2026.
- How has Corcept Therapeutics's total liabilities & equity changed year-over-year?
- Corcept Therapeutics's total liabilities & equity increased by 10.8% year-over-year, from $801.72M to $888.7M.
- What is the long-term trend for Corcept Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total liabilities & equity has grown at a 7.9% compound annual growth rate (CAGR), from $571.73M to $836.65M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Corcept Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude